Table 4.
Sensitivity analyses for the associations between dietary magnesium or calcium intake and severity of chronic chemotherapy-induced neuropathy.
| Beta (95% CI) | ||||||
|---|---|---|---|---|---|---|
| n | Total Score CIPN16 | n | Sensory Symptoms | n | Motor Symptoms | |
| Patients receiving oxaliplatin-containing chemotherapy | ||||||
| Magnesium | ||||||
| At diagnosis | 137 | −0.68 (−1.58, 0.22) | 138 | −1.01 (−1.97, −0.05) | 126 | −0.48 (−0.53, 0.57) |
| During chemotherapy | 136 | −0.90 (−1.80, −0.00) | 137 | −1.10 (−2.06, −0.14) | 125 | −1.28 (−2.33, −0.24) |
| After chemotherapy | 132 | −0.94 (−1.85, −0.02) | 133 | −1.10 (−2.07, −0.12) | 121 | −0.94 (−1.98, 0.10) |
| Calcium | ||||||
| At diagnosis | 137 | 0.00 (−0.42, 0.42) | 138 | 0.08 (−0.36, 0.53) | 132 | −0.19 (−0.63, 0.26) |
| During chemotherapy | 136 | −0.18 (−0.54; 0.18) | 137 | −0.11 (−0.51; 0.28) | 125 | −0.28 (−0.69; 0.13) |
| After chemotherapy | 132 | 0.00 (−0.39, 0.41) | 133 | −0.06 (−0.49, 0.38) | 121 | 0.01 (−0.43, 0.45) |
| Not supplement users | ||||||
| Magnesium | ||||||
| At diagnosis | 128 | −0.80 (−1.80, 0.20) | 126 | −0.99 (−2.08, 0.10) | 119 | −0.68 (−1.83, 0.48) |
| During chemotherapy | 136 | −1.24 (−2.21, −0.27) | 134 | −1.20 (−2.27, −0.13) | 128 | −1.81 (−2.90, −0.71) |
| After chemotherapy | 129 | −1.34 (−2.30, −0.37) | 126 | −1.29 (−2.37, −0.21) | 119 | −1.38 (−2.44, −0.32) |
| Calcium | ||||||
| At diagnosis | 127 | −0.06 (−0.50, 0.37) | 127 | 0.06 (−0.41, 0.53) | 119 | −0.08 (−0.56, 0.38) |
| During chemotherapy | 140 | −0.12 (−0.48, 0.23) | 138 | −0.07 (−0.45, 0.32) | 132 | −0.20 (−0.60, 0.20) |
| After chemotherapy | 127 | −0.00 (−0.41, 0.42) | 130 | −0.09 (−0.54, 0.36) | 119 | 0.09 (−0.35, 0.53) |
| Colon cancer patients | ||||||
| Magnesium | ||||||
| At diagnosis | 146 | −0.66 (−1.54, 0.22) | 145 | −1.11 (−2.04, −0.18) | 135 | −0.34 (−1.37, 0.68) |
| During chemotherapy | 145 | −1.13 (−2.03, −0.23) | 145 | −1.34 (−2.30, −0.38) | 134 | −1.30 (−2.33, −0.26) |
| After chemotherapy | 139 | −0.80 (−1.71, 0.11) | 137 | −0.98 (−1.95, −0.02) | 128 | −0.66 (−1.67, 0.36) |
| Calcium | ||||||
| At diagnosis | 146 | −0.00 (−0.42, 0.41) | 145 | 0.07 (−0.37, 0.51) | 135 | −0.15 (−0.58, 0.28) |
| During chemotherapy | 145 | −0.11 (−0.48, 0.25) | 145 | −0.07 (−0.47, 0.35) | 134 | −0.16 (−0.57, 0.26) |
| After chemotherapy | 139 | −0.03 (−0.45, 0.39) | 137 | −0.11 (−0.56, 0.34) | 128 | 0.04 (−0.41, 0.50) |
Analyses were performed using multivariable linear regression analyses. Models for magnesium was adjusted for energy-adjusted dietary calcium and vitamin D intake as well as age and gender. Models for calcium was adjusted for energy-adjusted dietary magnesium and vitamin D intake as well as age and gender.